Seegene, Inc.

KOSDAQ 096530.KQ

Seegene, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: 1,537.30

Seegene, Inc. Price to Earnings Ratio (P/E) is 1,537.30 on January 14, 2025, a -1.44% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Seegene, Inc. 52-week high Price to Earnings Ratio (P/E) is 2,313.01 on August 19, 2024, which is 50.46% above the current Price to Earnings Ratio (P/E).
  • Seegene, Inc. 52-week low Price to Earnings Ratio (P/E) is 1,291.04 on June 27, 2024, which is -16.02% below the current Price to Earnings Ratio (P/E).
  • Seegene, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is 1,544.30.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
KOSDAQ: 096530.KQ

Seegene, Inc.

CEO Dr. Jong-Yoon Chun
IPO Date Sept. 10, 2010
Location South Korea
Headquarters Taewon Building
Employees 63
Sector Health Care
Industries
Description

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Similar companies

086900.KQ

Medy-Tox Inc.

USD 83.61

0.82%

128940.KS

Hanmi Pharm. Co., Ltd.

USD 177.66

0.74%

207940.KS

Samsung Biologics Co.,Ltd.

USD 698.37

1.93%

068270.KS

Celltrion, Inc.

USD 125.83

1.12%

326030.KS

SK Biopharmaceuticals Co., Ltd.

USD 75.63

-3.02%

StockViz Staff

January 15, 2025

Any question? Send us an email